SOLIGENIX, INC. SNGX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-90.05
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$11.1M | — | -$10.3M | $5.3M |
| 2024 | $119,371 | -$8.3M | — | — | $4.1M |
| 2023 | $839,359 | -$6.1M | $97,311 | — | $2.5M |
| 2022 | $948,911 | -$13.8M | $398,089 | — | -$2.5M |
| 2021 | $824,268 | -$12.6M | $95,628 | — | $10.7M |
| 2020 | $2.4M | -$17.7M | $538,498 | — | $3.7M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| SCHABER CHRISTOPHER J | CHAIRMAN, CEO AND PRESIDENT | 2025-10-02 | Buy | 15,132 | $1.32 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -90.05 (distress)
- Working capital / assets 0.558
- Retained earnings / assets -26.534
- EBIT / assets -1.283
- Equity / liabilities 1.342
Source: SEC EDGAR filings · CIK 0000812796 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.